As a Free StocksGuide user, you can view scores for all 7,097 stocks worldwide.
18 Analysts have issued a Monopar Therapeutics Inc forecast:
18 Analysts have issued a Monopar Therapeutics Inc forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
|
| EBIT (Operating Income) EBIT | -19 -19 |
155%
155%
|
|
| Net Profit | -17 -17 |
143%
143%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Monopar Therapeutics, Inc. is a a clinical stage biopharmaceutical company, which engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline include Validive, Camsirubicin, and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
| Head office | United States |
| CEO | Chandler Robinson |
| Employees | 15 |
| Founded | 2014 |
| Website | www.monopartx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


